Hepatitis C virus infection in children and adolescents: a management update

Hepatitis C virus infection in children and adolescents: a management update

Abstract Hepatitis C virus infection is an emerging problem for children and adolescents. Chronic HCV infection affects approximately 3.5–5 million children worldwide. Unaddressed HCV infection in children progresses to decompensated liver disease and hepatocellular carcinoma during adulthood. Early...

Full description

Bibliographic Details
Main Authors:	Fahmida Begum, Md.Wahiduzzaman Mazumder, Khan Lamia Nahid, Tahmina Jesmin, Nadira Musabbir
Format:	Article
Language:	English
Published:	SpringerOpen 2023-04-01
Series:	Egyptian Pediatric Association Gazette
Subjects:	Children Adolescents Direct-acting antiviral Genotype Hepatitis C infection
Online Access:	https://doi.org/10.1186/s43054-023-00166-x

Similar Items

Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan
by: Mikhail Yu. Kartashov, et al.
Published: (2023-07-01)

Hepatitis C Treatment: A Review and Update
by: Jelena Jakab, et al.
Published: (2017-04-01)

Acute hepatitis C virus infection: clinical update and remaining challenges
by: Chen-Hua Liu, et al.
Published: (2023-07-01)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
by: Ken Sato, et al.
Published: (2022-04-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
by: Jong Eun Yeon
Published: (2018-09-01)

Treating Hepatitis C Virus Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014–2020
by: Justin Chan, MD, et al.
Published: (2024-04-01)

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office
by: Karem Aline Pegoraro, et al.
Published: (2023-11-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice
by: Farihah Malik, et al.
Published: (2022-03-01)

Hepatitis C treatment: where are we now?
by: Burstow NJ, et al.
Published: (2017-02-01)

Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway
by: Carmen F. Manso, et al.
Published: (2020-10-01)

Pediatric perspectives on treating uncommon genotypes of hepatitis C in the United States
by: Vorada Sakulsaengprapha, et al.
Published: (2021-01-01)

Antiviral therapy in chronic hepatitis C virus infection
by: Irina Russu
Published: (2019-09-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01)

Current Treatment Of Chronıc Hepatıtıs C Genotype 1
by: Mesut Aydın, et al.
Published: (2018-10-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
by: Paweł Pabjan, et al.
Published: (2022-01-01)

Persistent Transcriptional Alterations after Hepatitis C Virus Elimination in Cell Culture
by: Victoria Castro, et al.
Published: (2020-06-01)

Genotype distribution, intravenous drug use rates and direct-acting antiviral treatment results in prisoner hepatitis C patients
by: Ö. Şahin, et al.
Published: (2023-04-01)

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
by: Yuri Cho, et al.
Published: (2015-12-01)

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
Published: (2018-09-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
by: Erica Nicola Lynch, et al.
Published: (2023-03-01)

Early Experience of Sofosbuvir based Combination Therapy in “Real-Life” Cohort with Chronic Hepatitis-C Infection
by: Rajiv Mehta, et al.
Published: (2017-03-01)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
by: Hsu-Heng Yen, et al.
Published: (2021-03-01)

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2021-10-01)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
by: Mohit Bhatia, et al.
Published: (2020-01-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01)

The Outcomes of Direct-acting Antiviral Treatment in 177 Patients with Hepatitis C Virus: A Single-center Experience
by: Ayşin KILINÇ TOKER, et al.
Published: (2023-12-01)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
by: Pil Soo Sung, et al.
Published: (2021-01-01)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01)

The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis
by: Na He, et al.
Published: (2022-07-01)

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT
by: Graham S Cooke, et al.
Published: (2021-10-01)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
by: Childs-Kean LM, et al.
Published: (2019-07-01)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs
by: Amira Isaac, et al.
Published: (2021-12-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Efficacy of Interferonfree treatment for patients with chronic hepatitis C virus
by: Valeria Muntean, et al.
Published: (2019-05-01)